Compare iShares Bitcoin Trust (IBIT) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Bitcoin Trust vs Organon & Co. Common Stock — how do they compare? iShares Bitcoin Trust trades at $45.94 (market cap $66.43B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: iShares Bitcoin Trust is far larger — about 18.4× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while iShares Bitcoin Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Bitcoin Trust for 42 Days and Organon & Co. Common Stock for 0 Days on average.
| IBIT | OGN | |
|---|---|---|
Market Cap | $66.43B | $3.62B |
Volume | 28,050,093 | 2,892,999 |
Sector | Crypto-linked | Health |
52-Week High | $65.28 | $13.81 |
52-Week Low | $33.29 | $5.70 |
Typical Hold Time | 42 Days | 0 Days |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $47.13, up 0.58% with neutral technical signals overall. The stock shows bullish moving average momentum but mixed oscillators, with key support at $46 and resistance at $48. Recent institutional inflows and positive ETF performance highlight growing investor interest in BlackRock's Bitcoin trust vehicle, though financial ratios remain undisclosed in current filings.
Outlook remains cautiously optimistic given strong institutional inflows and market positioning. Key risks include regulatory uncertainty and Bitcoin price volatility affecting the trust's underlying value. Analyst sentiment appears balanced with technical indicators suggesting near-term consolidation around current levels.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
